Search results: Found 9

Listing 1 - 9 of 9
Sort by
Immunomodulatory Effects of Drugs for Treatment of Immune-Related Diseases

Author:
Book Series: Frontiers Research Topics ISSN: 16648714 ISBN: 9782889452880 Year: Pages: 108 DOI: 10.3389/978-2-88945-288-0 Language: English
Publisher: Frontiers Media SA
Subject: Medicine (General) --- Allergy and Immunology
Added to DOAB on : 2018-02-27 16:16:44
License:

Loading...
Export citation

Choose an application

Abstract

More than 90% of diseases possess immunological abnormalities. Disorders such as inflammation, hypersensitivity, autoimmunity and immunodeficiency are simple examples of how the immune system misinterprets its surroundings and goes awry. Multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel diseases, among many others are manifestations of immune cells attacking normal tissues. On the other hand, damping the immune system leads to diseases such as cancer, AIDS, and severe combined immunodeficiency. The last ten years witnessed an explosion in developing drugs that target the immune system. Several novel monoclonal antibodies have been approved for treatment of various diseases confirming that personalized medicine approach is robust in combating diseases. Hence, the future holds great promise for using personalized and targeted medicine rather than generalized medications that, in most circumstances, proven to be ineffective and characteristically exert side effects. Approaches such as generating novel adjuvants that can stimulate the immune system without harmful side effects, targeting inflammatory cytokines and chemokines, harnessing and activating innate immune cells such as natural killer cells or dendritic cells, are examples of future approaches to treat autoimmune diseases, AIDS, and various forms of cancer resulting from chronic inflammation. More recently, targeting immune checkpoint molecules have shown therapeutic response against lung cancer and melanoma. Identifying molecules involved in autophagy is another example of how personalized medicine might help treat patients with refractory asthma and autoimmune diseases. This topic introduces the reader to these novel approaches of manipulating the immune system and developing targeted therapeutic strategies for treatment of various diseases.

The Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine

Authors: ---
Book Series: Frontiers Research Topics ISSN: 16648714 ISBN: 9782889195435 Year: Pages: 140 DOI: 10.3389/978-2-88919-543-5 Language: English
Publisher: Frontiers Media SA
Subject: Oncology --- Medicine (General)
Added to DOAB on : 2016-01-19 14:05:46
License:

Loading...
Export citation

Choose an application

Abstract

Lung cancer is the leading cause of cancer related mortality in Canada and USA. Majority of the patients present in advanced stage of the disease and of these only about 2% will be alive at 5 years. NSCLC is the most common form of lung cancer, accounting for approximately 87% of cases. Systemic chemotherapies have been used to treat metastatic NSCLC for decades, but the improvements of outcomes have reached a plateau. Recent advances in understanding signalling pathways for malignant cells, their interconections,the importance of various receptors and biomarkers and the interplay between various oncogenes have led to the development of targeted treatments that are improving both efficacy and safety of the treatments. Knowledge about the advantages of treatments with the targeted agents in metastatic NSCLC is growing rapidly. Combining various targeted agents or sequencing them properly will be important in the era of personalised medicine and overcoming development of the resistence to various targeted agents will be challenging. The importance of a team work,from the diagnosis through various treatments, to supportive care, from the interventional radiologists, pneumologists or surgeons, who have to obtain a satisfactory tumor tissue specimen, to pathologists, radiation and medical oncologists, to supportive care specialists, will be described in our publications. We will cover completely present and future approaches to personalised medicine in this rapidly evolving field of metastatic NSCLC.

MicroRNA as Biomarkers in Cancer Diagnostics and Therapy

Author:
ISBN: 9783039212491 9783039212507 Year: Pages: 166 DOI: 10.3390/books978-3-03921-250-7 Language: English
Publisher: MDPI - Multidisciplinary Digital Publishing Institute
Subject: Science (General) --- Biology --- Microbiology
Added to DOAB on : 2019-08-28 11:21:27
License:

Loading...
Export citation

Choose an application

Abstract

This Special Issue celebrates the 25th anniversary of the discovery of the first microRNA. The size of the microRNome and complexity of animal body plans and organ systems suggests a role for microRNAs in cell fate determination and differentiation. More than 2000 sequences have been proposed to represent unique microRNA genes in humans, with an increasing number of mechanistic roles identified in developmental, physiological, and pathological processes. Thus, dysregulation of a few key microRNAs can have a profound global effect on the gene expression and molecular programs of a cell. This great potential for clinical intervention has captured the interest and imagination of researchers in many fields. However, very few fields have been as prolific as the field of cancer research. This Special Issue provides but a glimpse of the large body of literature of microRNA biology in cancer research, containing 4 original research studies and 4 review articles that focus on specific hematologic or solid tumors in disease. Collectively, these articles highlight state-of-the-art approaches and methodologies for microRNA detection in tissue, blood, and other body fluids in a range of biomarkers applications, from early cancer detection to prognosis and treatment response. The articles also address some of the challenges regarding clinical implementation.

microRNA Regulation in Health and Disease

Authors: ---
ISBN: 9783039217144 9783039217151 Year: Pages: 154 DOI: 10.3390/books978-3-03921-715-1 Language: English
Publisher: MDPI - Multidisciplinary Digital Publishing Institute
Subject: Science (General) --- Biology --- Genetics
Added to DOAB on : 2020-04-07 23:07:08
License:

Loading...
Export citation

Choose an application

Abstract

MicroRNAs (miRNAs) are small regulatory RNAs that play a crucial role in posttranscriptional gene regulation. Over two thousand miRNAs have been identified in humans, and many of them are conserved in other species. miRNAs are implicated in fundamental cellular functions, including development and disease. In the last decade, there has been an overwhelming amount of data contributing to the understanding of miRNA biogenesis and their target genes. Moreover, a significant amount of work has been carried out in developing miRNA biomarkers and therapeutics for various disease conditions. RNA-based markers and therapeutics have been proven to have a clinical impact, and many of these miRNA-based therapies are at various stages of human clinical trials and clinical applications. Notably, miRNAs are also found in exosomes, and are considered to impart intercellular communication and function via several different modalities, including tunneling nanotubes. In spite of our understanding of miRNA biology and function, there are many challenges in effectively using miRNAs as biomarkers and therapeutic agents in clinical applications. In this Special Issue, we are inviting reviews, perspectives, and original research articles to address some of these challenges. Topics will include, but are not limited to, miRNA biogenesis, clinical applications, extracellular function, biomarkers, miRNA immune regulation, signaling pathways, and preclinical models.

Microbial Biofilms in Healthcare: Formation, Prevention and Treatment

Author:
ISBN: 9783039284108 9783039284115 Year: Pages: 166 DOI: 10.3390/books978-3-03928-411-5 Language: English
Publisher: MDPI - Multidisciplinary Digital Publishing Institute
Subject: Science (General) --- Biology --- Microbiology
Added to DOAB on : 2020-04-07 23:07:09
License:

Loading...
Export citation

Choose an application

Abstract

Biofilms are ubiquitous and their presence in industry can lead to production losses. However, nowhere do biofilms impact human health and welfare as much as those that are found contaminating the healthcare environment, surgical instruments, equipment, and medical implantable devices. Approximately 70% of healthcare-associated infections are due to biofilm formation, resulting in increased patient morbidity and mortality. Biofilms formed on medical implants are recalcitrant to antibiotic treatment, which leaves implant removal as the principal treatment option. In this book, we investigate the role of biofilms in breast and dental implant disease and cancer. We include in vitro models for investigating treatment of chronic wounds and disinfectant action against Candida sp. Also included are papers on the most recent strategies for treating biofilm infection ranging from antibiotics incorporated into bone void fillers to antimicrobial peptides and quorum sensing.

Venom and Toxin as Targeted Therapy

Author:
ISBN: 9783039211890 9783039211906 Year: Pages: 180 DOI: 10.3390/books978-3-03921-190-6 Language: English
Publisher: MDPI - Multidisciplinary Digital Publishing Institute
Subject: Science (General) --- Biology
Added to DOAB on : 2019-12-09 11:49:15
License:

Loading...
Export citation

Choose an application

Abstract

Targeted therapy has developed significantly in the last one and half decades, prescribing specific medications for treatment of particular diseases, such as cancer, diabetes, and heart disease. One of the most exciting recent developments in targeted therapies was the isolation of disease-specific molecules from natural resources, such as animal venoms and plant metabolites/toxins, for use as templates for new drug motif designs. In addition, the study of venom proteins/peptides and toxins naturally targeted mammalian receptors and demonstrated high specificity and selectivity towards defined ion channels of cell membranes. Research has also focsed intensely on receptors. The focus of this Special Issue of Toxins addressed the most recent advances using animal venoms, such as frog secretions, bee/ant venoms and plant/fungi toxins, as medicinal therapy. Recent advances in venom/toxin/immunotoxins for targeted cancer therapy and immunotherapy, along with using novel disease-specific venom-based protein/peptide/toxin and currently available FDA-approved drugs for combinationtreatments will be discussed. Finally, we included an overview of select promising toad/snake venom-based peptides/toxins potentially able to address the forthcoming challenges in this field. Both research and review articles proposing novelties or overviews, respectively, were published in this Special Issue after rigorous evaluation and revision by expert peer reviewers.

Keywords

disintegrin --- blood vessel formation --- VEGF --- antioxidant enzymes --- oxidative stress biomarkers --- bicarinalin --- antimicrobial peptide --- Helicobacter pylori --- gastric cells --- bacterial adhesion --- SEM --- atopic dermatitis (AD) --- house dust mite extract (DFE) --- 2,4-dinitrochlorobenzene (DNCB) --- bee venom phospholipase A2 (bvPLA2) --- skin inflammation --- CD206 --- mannose receptor --- immunotoxin --- Moxetumomab pasudotox --- targeted therapy --- CD22 --- B cell non-Hodgkin lymphoma --- acute lymphoblastic leukemia --- mantle cell lymphoma --- ribosome-inactivating protein --- BLF1 --- eIF4A --- MYCN --- cancer --- neuroblastoma --- apoptosis --- antimicrobial peptide (AMP) --- dermaseptin --- anuran skin secretion --- drug design --- antimicrobial activity --- anticancer activity --- antiviral activity --- Bougainvillea --- bouganin --- cancer therapy --- immunotherapy --- immunotoxins --- ribosome-inactivating proteins --- rRNA N-glycosylase activity --- VB6-845 --- orellanine --- clearance --- fungal toxin --- half-life --- toad toxins --- Chansu --- Huachansu --- cane toad --- bufadienolides --- indolealkylamines --- inflammation --- cancer --- obsessive–compulsive disorder (OCD) --- snake venom --- cancer --- target therapy --- snake venom --- Malaysian cobras --- N. kaouthia --- N. sumatrana --- O. hannah --- anticancer --- Apis mellifera syriaca --- bee venom --- melittin --- LC-ESI-MS --- solid phase extraction --- in vitro effects --- frog --- mass spectrometry --- molecular cloning --- bombesin-related peptide --- smooth muscle --- Bee venom --- complement system --- decay accelerating factor --- atopic dermatitis --- complement dependent cytotoxicity --- membrane attack complex --- n/a

Fungal Infections in Immunocompromised Hosts

Authors: ---
ISBN: 9783038977162 Year: Pages: 212 DOI: 10.3390/books978-3-03897-717-9 Language: English
Publisher: MDPI - Multidisciplinary Digital Publishing Institute
Subject: Microbiology --- Biology --- Science (General)
Added to DOAB on : 2019-04-05 10:34:31
License:

Loading...
Export citation

Choose an application

Abstract

This book is a printed edition of the Special Issue Fungal Infections in Immunocompromised Hosts that was published in JoF

Keywords

Candida auris --- Aspergillus fumigatus --- antifungal resistance --- multidrug resistance --- mechanisms of antifungal resistance --- liver disease --- hepatic impairment --- invasive fungal infection --- antifungal agent --- antifungal drug --- toxicity --- Immunotherapy --- invasive aspergillosis --- Aspergillus fumigatus --- fungal infections --- innate immunity --- adaptive immunity --- cell therapy --- cytokine therapy --- taxonomy --- fungal nomenclature --- phylogenetics --- species complex --- invasive fungal infections --- mycoses --- immune reconstitution inflammatory syndrome --- fungal immunity --- prognostic risk model --- prediction models --- risk score --- invasive mold disease --- hematological malignancy --- risk assessment --- antifungal stewardship --- paracoccidioidomycosis --- HIV --- cancer --- lymphoma --- kidney transplant --- TNF inhibitors --- literature review --- MALDI-ToF MS --- yeast --- fungus --- AIDS --- IRIS --- cat-transmitted sporotrichosis --- immunocompromised hosts --- mycoses of implantation --- sporotrichosis --- Sporothrix brasiliensis --- Sporothrix schenckii --- subcutaneous mycoses --- invasive fungal infection --- non-culture-based diagnostics --- aspergillosis --- candidiasis --- Aspergillus PCR --- galactomannan --- lateral flow --- beta-d-glucan --- T2 Candida --- candidemia --- Candida meningoencephalitis --- (1?3)-?-d-glucan --- T2Candida --- PCR --- liposomal amphotericin B --- micafungin --- anidulafungin --- Aspergillus --- anti-fungal agents --- hematological malignancies

Links between Fibrogenesis and Cancer: Mechanistic and Therapeutic Challenges: Mechanistic and Therapeutic Challenges

Author:
ISBN: 9783039217069 9783039217076 Year: Pages: 348 DOI: 10.3390/books978-3-03921-707-6 Language: English
Publisher: MDPI - Multidisciplinary Digital Publishing Institute
Subject: Medicine (General) --- Internal medicine
Added to DOAB on : 2019-12-09 11:49:16
License:

Loading...
Export citation

Choose an application

Abstract

Tissue fibrosis may occur for unknown causes or be the consequence of many pathological conditions including chronic inflammatory or infectious diseases, autoimmune disorders, graft rejection, or malignancy. On the other hand, malignant tumors have been identified in fibrotic tissues decades ago, and now accumulating evidence suggests that fibrotic lesions enhance the risk of cancer in several organs such as liver, lungs, and breast. Disruption of an organ parenchymal cells and of its normal structural scaffold during tissue fibrogenesis appears to induce loss of cell polarity, promoting uncontrolled cell proliferation that may eventually lead to cancer development. Many cellular and molecular abnormalities including aberrant expression of microRNAs, genetic and epigenetic alterations, evasion or delayed apoptosis, unregulated intracellular signal pathways, and dysregulation or defective intercellular communications have been proposed to explain this link between fibrogenesis and carcinogenesis. However, the precise mechanisms of this fibrosis-to-cancer transition remain unclear. This book presents a collection of reviews and original articles summarizing recent advances in understanding the molecular mechanisms of cancer development in fibrotic organs.

Keywords

lung cancer --- renal injury --- fibrosis --- crizotinib --- anaplastic lymphoma kinase --- cystic formation --- pulmonary fibrosis --- butylidenephthalide --- SOX2 --- type I collagen --- bleomycin --- YAP --- TAZ --- Hippo pathway --- fibrosis --- cancer --- mechanotransduction --- TGF-? --- Wnt --- uterine fibroid --- leiomyoma --- tumor --- tumor necrosis factor ? --- cytokine --- growth factor --- inflammation --- clinical symptoms --- pathophysiology --- therapy --- hepatocellular carcinoma --- cirrhosis --- regeneration --- inflammation --- cytokines --- genetic instability --- reactive oxygen species --- idiopathic pulmonary fibrosis (IPF) --- lung cancer (LC) --- non-small cell lung cancer (NSCLC) --- acute lung injury --- protein S --- apoptosis --- signal pathway --- Erk1/2 --- lipopolysaccharide --- uterine fibroid --- leiomyoma --- smooth muscle tumor of uncertain malignant potential --- leiomyosarcoma --- myometrium --- immunohistochemistry --- marker --- pathology --- tumor --- diagnosis --- cancer-associated fibroblasts --- tumor microenvironment --- nanoparticles --- breast cancer --- antitumor efficacy --- cirrhosis --- HBV --- HCV --- hepatocellular carcinoma --- idiopathic pulmonary fibrosis --- lung cancer --- pathogenesis --- common pathways --- hepatocellular carcinoma (HCC) --- fibrosis --- cancer-associated fibroblasts (CAFs) --- hepatic stellate cells (HSCs) --- tumor microenvironment --- hepatocellular carcinoma --- non-alcoholic steatohepatitis --- fibrosis --- hepatic stellate cells --- extracellular matrix --- carcinogenesis --- angiogenesis --- cancer-associated fibroblasts --- extracellular matrix --- fibrosis --- heterogeneity --- interstitial fluid pressure --- metabolic reprogramming --- transforming growth factor-? --- tumor stiffness --- GPR40 --- GPR120 --- DHA --- omega-3 fatty acid --- SREBP-1 --- hepatocytes --- EMT --- lncRNA --- metastasis --- miRNA --- SMAD --- TGF-? --- targeted therapy --- tumor microenvironment --- n/a

Renal Cell Carcinoma

Author:
ISBN: 9783039286386 / 9783039286393 Year: Pages: 500 DOI: 10.3390/books978-3-03928-639-3 Language: eng
Publisher: MDPI - Multidisciplinary Digital Publishing Institute
Subject: Science (General) --- Biology
Added to DOAB on : 2020-06-09 16:38:57
License:

Loading...
Export citation

Choose an application

Abstract

Renal cancer is a health problem of major concern worldwide. Although tyrosine kinase inhibitors and immune check-point blockade treatments, alone or in combination, are giving promising results, failures are quite frequent due to intratumor heterogeneity and to the acquisition of drug resistance. The spectrum of renal cell carcinoma subtypes is wide. Up to 70–80% of renal tumors are clear cell renal cell carcinomas, a clinically aggressive tumor subtype linked to VHL gene inactivation. Next in frequency, the papillary renal cell carcinoma category encompasses an intricate puzzle of classic and newly described entities with poorly defined limits, some of them pending definite clarification. Likewise, the chromophobe–oncocytoma duality, the so-called hybrid tumors and oncocytic neoplasms, remain to be well profiled. Finally, a growing list of very uncommon renal tumors linked to specific molecular signatures fulfill the current portrait of renal cell neoplasia. This Special Issue of Cancers regards RCC from very different perspectives, from the intimate basic mechanisms governing this disease to the clinical practice principles of their diagnoses and treatments. The interested reader will have the opportunity to contact with some of the most recent findings and will be updated with excellent reviews.

Keywords

ghrelin --- aurora A --- MMP10 --- invasion --- sarcomatoid --- RCC --- immunotherapy --- checkpoint inhibitors --- survival --- PD-L1 --- chronic kidney disease --- nephrectomy --- overall survival --- recurrence free survival --- renal cell carcinoma --- statins --- uric acid --- intratumour heterogeneity --- metastatic ccRCC --- copy number alteration --- mutation --- gene expression --- MiT family translocation renal cell carcinoma --- Xp11 translocation renal cell carcinoma --- t(6 --- 11) translocation renal cell carcinoma --- FISH --- TFE3 --- TFEB --- TFEB-amplified renal cell carcinoma --- renal cell carcinoma --- immune checkpoint inhibitors --- tyrosine kinase inhibitors --- efficacy --- toxicity --- cytoreductive nephrectomy --- Papillary renal cell carcinoma (pRCC) --- proteome profiling --- metabolome profiling --- glutathione metabolism --- metabolic reprogramming --- IL4R? --- IL13R?1 --- renal cell carcinoma --- JAK2 --- FOXO3 --- clear cell renal cell carcinoma --- identification of circular RNAs --- experimental validation of circular RNA --- diagnostic and prognostic markers --- circular RNAs in a clinico-genomic predictive model --- cancer-specific survival --- recurrence-free survival --- overall survival --- chromophobe renal cell carcinoma --- pale cell --- eosinophilic variant --- chromosomal loss --- copy number analysis --- renal cell carcinoma --- clear cell renal cell carcinoma --- AMP-activated protein kinases --- immunohistochemistry --- prognosis --- SMAD proteins --- transforming growth factor beta --- renal cell cancer --- microRNA --- metabolome --- proliferation --- PPP --- pentose phosphate pathway --- TCA cycle --- miR-155-5p --- miR-146a-5p --- TCGA --- renal cell carcinoma --- metastasis --- MTA2 --- MMP-9 --- miR-133b --- kidney cancer --- immunotherapy --- renal cell --- inflammation markers --- programmed death-ligand 1 --- immune checkpoint inhibitors --- prognostic factors --- predictive factors --- glutathione transferase omega 1 --- glutathione transferase omega 2 --- polymorphism --- PI3K/Akt/mTOR --- Raf/MEK/ERK --- IL-1? --- pro-IL-1? --- gene signature --- renal cancer --- survival prediction --- polybromo-1 --- PBRM1 --- renal cell carcinoma --- biomarker --- prognosis --- predictive role --- collecting duct carcinoma --- RNA sequencing --- solute carrier proteins --- kidney --- renal cell carcinoma --- molecular genetic features --- practical approach --- review --- renal cell carcinoma --- sarcomatoid --- immunotherapy --- renal cell carcinoma --- checkpoint inhibitors --- VEGF inhibitors --- mTOR inhibitors --- kidney --- emerging entity --- new entity --- oncocytic renal tumor --- unclassified renal cell carcinoma --- unclassified renal tumor --- anaplastic lymphoma kinase rearrangement --- ALK --- ESC --- HOT --- LOT --- drug sensitivity --- immune infiltration --- renal cancer --- targeted therapy --- tumor slice culture --- clear cell Renal Cell Carcinoma --- urine --- glycoproteomics --- N-glycomapping --- label-free --- glycomarkers --- everolimus --- EVI1 --- genetic association --- mTOR --- clear cell renal cell carcinoma --- curcumin --- renal cell cancer --- tumor adhesion --- tumor migration --- integrins --- NK cells --- kidney cancer --- renal cell carcinoma --- IL-2 --- cancer immunotherapy --- tumor microenvironment --- von Hippel–Lindau --- EMT like --- hyperosmolality --- chromophobe renal cell carcinoma --- copy number loss --- CDKN1A expression --- patient survival --- prognosis --- n/a

Listing 1 - 9 of 9
Sort by
Narrow your search